How can bleeding or spotting be managed in a patient with a Mirena (levonorgestrel-releasing intrauterine device) in situ?

Management of Bleeding and Spotting with Mirena In Situ

For patients experiencing bleeding or spotting with a Mirena (levonorgestrel-releasing intrauterine system) in place, first-line treatment is NSAIDs for 5–7 days during the bleeding episode, which can be repeated as needed. 1

Initial Assessment and Exclusion of Serious Causes

Before initiating any treatment for bleeding with Mirena in situ, you must systematically exclude:

• Pregnancy – this is the absolute first step in any woman with abnormal bleeding 1
• Pelvic infection – particularly important in IUD users; purulent discharge, fever ≥38°C, or lower abdominal pain warrant urgent evaluation within 24–48 hours 2, 3
• Sexually transmitted infections – obtain cervical specimens for Chlamydia trachomatis and Neisseria gonorrhoeae testing when clinically indicated 1, 2
• Thyroid dysfunction – check TSH if symptoms suggest thyroid disease 1
• Structural pathology – evaluate for new polyps, fibroids, or malignancy 1
• Medication interactions – review current medications that may affect bleeding 1

First-Line Pharmacologic Management

NSAIDs remain the cornerstone of treatment for bleeding with Mirena in place:

• Administer NSAIDs for 5–7 days during each bleeding episode – this can be repeated with subsequent episodes as needed 1
• Specific NSAID options include:
  • Ibuprofen (standard dosing) 1
  • Mefenamic acid 500 mg three times daily 1
  • Celecoxib 1

Important Context on NSAID Efficacy

While CDC guidelines recommend NSAIDs as first-line therapy 1, a 2013 randomized controlled trial found that neither tranexamic acid nor mefenamic acid significantly reduced bleeding days in the first 90 days after Mirena placement (median 25 days with tranexamic acid vs 33 days with placebo, difference of 6 days, 95% CI -14.0 to 1.0) 4. Despite this, NSAIDs remain guideline-recommended first-line therapy and should be tried before escalation.

Second-Line Hormonal Therapy (When NSAIDs Fail)

If bleeding persists or is heavy despite NSAIDs, add short-course hormonal therapy for 10–20 days: 1

• Low-dose combined oral contraceptives (if medically eligible) 1
• Estrogen alone as an alternative 1

Third-Line: Tranexamic Acid

• Tranexamic acid for a 5-day course can be offered for heavy or prolonged bleeding 1
• Note: The 2013 RCT showed limited benefit in the immediate post-insertion period 4, but it remains a guideline-recommended option for persistent cases

Expected Bleeding Patterns and Counseling

Set realistic expectations with patients about bleeding patterns during the first year:

• Bleeding and/or spotting gradually decreases from 35.6 days in the first 90-day interval to 11.7 days by days 271–360 5
• The greatest decrease occurs between months 3 and 6 (from 35.6 days to 19.1 days) 5
• Overall incidence of spotting is 50% 6
• Amenorrhea develops in 14% of patients 6
• Most women (85% or more) remain satisfied with the Mirena despite initial bleeding changes 4

When to Consider Device Removal

If spotting remains bothersome despite counseling and a trial of NSAIDs, counsel the patient about switching to an alternative contraceptive method. 3 This applies particularly to:

• Women whose irregular bleeding persists beyond 6 months (the expected adaptation period) 3
• Patients in whom medical management has failed after appropriate trials 1

Efficacy by Underlying Pathology

The effectiveness of Mirena varies significantly by the cause of bleeding: 6

• 95.5% effective for endometrial hyperplasia 6
• 92.3% effective for unclassified abnormal uterine bleeding 6
• 88.7% effective for adenomyosis 6
• Only 55.6% effective for leiomyoma – these patients are more likely to require surgical intervention 6

Escalation and Referral

If appropriate medical therapy fails, proceed with imaging (ultrasound) or hysteroscopic evaluation to identify structural lesions 1. Refer when:

• Medical management is unsuccessful after a reasonable trial 1
• There is suspicion of malignancy or significant structural pathology 1

Critical Pitfalls to Avoid

• Do not delay evaluation of purulent discharge – assume infection until proven otherwise; normal IUD-related discharge should never be purulent 2
• Do not remove the IUD before medical evaluation unless a clinician determines it necessary after excluding infection 2
• Do not assume all bleeding is hormonal – younger age and severe dysmenorrhea are associated with higher discontinuation rates 7
• Do not continue ineffective treatment indefinitely – if NSAIDs and hormonal therapy fail by 6 months, reassess for structural causes or consider device removal 3